Drug lookup
Drug reference

Naldemedine

Antidote · Treatment of Opioid-Induced Constipation

Also known as Naldemedine tosylate, Rizmoic

AntidoteTreatment of Opioid-Induced ConstipationATC A06AH03
CDSCO approvedSchedule HATC A06AH03
EXCRETION
not curated
INTERACTIONS
11 major
SEVERE in our sources
PREGNANCY
Manufacturer advises avoid unless potential benefit outweighs risk— animal studies do not indicate toxicity; risk of opioid withdrawal in fetus.
FDA category + note
Top interactionssee all 11
  • ApalutamideSevereDatabaseDDInter
  • CarbamazepineSevereDatabaseDDInter
  • EnzalutamideSevereDatabaseDDInter
  • FosphenytoinSevereDatabaseDDInter

Mechanism

Naldemedine is a peripherally acting opioid receptor antagonist. It decreases the constipating effects of opioids without altering their central analgesic effects. Its principal mechanism for the selective therapeutic effect is peripheral enteric μ-receptor antagonism with minimal CNS penetration.

Indications

Opioid-induced constipation [previous treatment with a laxative]Constipation in patients with opioid-induced constipation (OIC) with chronic noncancer pain and late-stage advanced illnessOpioid-induced constipation (in adult patients with chronic noncancer pain)

Dosing

Adult
200 micrograms once daily
Renal adjustment
If eGFR less than 30 mL/minute/1.73 m2, reduce dose as follows: body-weight under 62 kg, 75 micrograms/kg on alternate days; body-weight 62–114 kg, 8 mg on alternate days; body-weight over 114 kg, 75 micrograms/kg on alternate days.
Hepatic adjustment
Manufacturer advises avoid in severe impairment (no information available)
Geriatric
Treatment initiation in patients aged 75 years and over (limited information available)

Pharmacokinetics

Peak effect
Approximately 45 min (fasted state); ~2.5 h (with food)
Half-life
11 h
Metabolism
Hepatic CYP3A
Excretion
57% in urine, 35% in feces

Contraindications

  • Increased risk of recurrent obstruction (risk of gastro-intestinal perforation)
  • Known or suspected gastro-intestinal obstruction (risk of gastro-intestinal perforation)
  • Known or suspected obstruction of the GI tract

Side effects

Common
Abdominal painDiarrheaNauseaVomitingGastroenteritis
Serious
  • Gastro-intestinal perforation
  • Severe, persistent or worsening gastro-intestinal effects (such as abdominal pain)
  • Opioid withdrawal syndrome
  • Opioid withdrawal (may be precipitated)

Pregnancy & lactation

Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk— animal studies do not indicate toxicity; risk of opioid withdrawal in fetus.

Lactation

Manufacturer advises avoid—present in milk in animal studies; theoretical risk of opioid withdrawal in breast-fed neonate.

Drug interactions

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Carbamazepine
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Enzalutamide
Severe
Database

Clinical effect not specified

Source: DDInter

Fosphenytoin
Severe
Database

Clinical effect not specified

Source: DDInter

Lumacaftor
Severe
Database

Clinical effect not specified

Source: DDInter

Mitotane
Severe
Database

Clinical effect not specified

Source: DDInter

Phenobarbital
Severe
Database

Clinical effect not specified

Source: DDInter

Phenytoin
Severe
Database

Clinical effect not specified

Source: DDInter

Primidone
Severe
Database

Clinical effect not specified

Source: DDInter

Rifampicin
Severe
Database

Clinical effect not specified

Source: DDInter

Rifapentine
Severe
Database

Clinical effect not specified

Source: DDInter

1 additional low-confidence interaction hidden — those rows lack a documented mechanism or management plan in our sources.

Related guidelines

Other Antidote drugs

Ask House about Naldemedine

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team